Treatment-resistant hypertension is a prevalent and life-threatening condition. At present, renal denervation is the most used non-pharmaceutical therapeutic approach. Optimal medical therapy (OMT) is the current standard.The aim of this HTA report is to assess the potential benefits and risk of renal denervation for treatment-resistant hypertension in addition to OMT compared with OMT alone.
